Delving into the Latest Updates on Tergene Biotech Pvt Ltd. with Synapse

概览

疾病领域	数量

感染	1

排名前五的药物类型	数量

治疗性疫苗	1
结合疫苗	1

关联

1

项与 Tergene Biotech Pvt Ltd. 相关的药物

Multivalent pneumococcal conjugate vaccine(Tergene Biotech Pvt Ltd.)

靶点-

作用机制

免疫刺激剂

在研机构

Tergene Biotech Pvt Ltd.

原研机构

Tergene Biotech Pvt Ltd.

在研适应症

肺炎

非在研适应症-

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期-

3

项与 Tergene Biotech Pvt Ltd. 相关的临床试验

CTRI/2022/10/046401 / Active, not recruiting临床3期

A Phase 3, Observer blind, Randomized, Active-Controlled Trial Evaluating the Immunologic Non-inferiority, Safety and Tolerability of a 15-valent Pneumococcal Conjugate Vaccine Compared to a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given in a Reduced Dosing Schedule with Routine Pediatric Vaccinations. - NA

开始日期2022-10-17

申办/合作机构

Tergene Biotech Pvt Ltd.

CTRI/2021/04/032693 / Active, not recruiting临床3期

A Phase 3, Observer blind, Randomized, Active-Controlled Trial Evaluating the Immunologic Non-inferiority, Safety and Tolerability of a 15-valent Pneumococcal Conjugate Vaccine Compared to a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given with Routine Pediatric Vaccinations. - NA

开始日期2021-06-25

申办/合作机构

Tergene Biotech Pvt Ltd.

CTRI/2019/02/017527 / Completed临床2期

A Multi-Centre, Open label, Randomized (1:1), Parallel, Phase II Study to evaluate the Safety, Tolerability and Immunogenicity of a 15-Valent Pneumococcal Conjugate Vaccine (PCV15) in healthy subjects between 2-5 years of age (Group I: 15-Valent Pneumococcal Conjugate Vaccine, Group II: Prevnar 13Â®).

开始日期2019-02-25

申办/合作机构

Tergene Biotech Pvt Ltd.

100 项与 Tergene Biotech Pvt Ltd. 相关的临床结果

登录后查看更多信息

0 项与 Tergene Biotech Pvt Ltd. 相关的专利（医药）

登录后查看更多信息

100 项与 Tergene Biotech Pvt Ltd. 相关的药物交易

登录后查看更多信息

100 项与 Tergene Biotech Pvt Ltd. 相关的转化医学

登录后查看更多信息